LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer

Kohei Nakata, Kenoki Ouchida, Eishi Nagai, Akifumi Hayashi, Yoshihiro Miyasaka, Tadashi Kayashima, Jun Yu, Shinichi Aishima, Yoshinao Oda, Kazuhiro Mizumoto, Masao Tanaka, Masazumi Tsuneyoshi

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

PURPOSE: LIM domain only 2 (LMO2) has been identified as a novel oncogene associated with carcinogenesis and better prognosis in several malignant tumors. We investigate the involvement of LMO2 in pancreatic cancer. EXPERIMENTAL DESIGN: We evaluated LMO2 expression in cultured cells, bulk tissues, and microdissected cells from pancreatic cancers by quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. RESULTS: Of 164 pancreatic cancers, 98 (60%) were positive for LMO2 expression. LMO2 was more frequently detected in high-grade pancreatic intraepithelial neoplasia (PanIN) lesions (PanIN-2 and -3) than in low-grade PanIN lesions (PanIN-1A and -1B; P < .001) and was not detected in normal pancreatic ductal epithelium. The LMO2 messenger RNA levels were significantly higher in invasive ductal carcinoma cells than in normal pancreatic cells as evaluated by quantitative reverse transcription-polymerase chain reaction analyses of microdissected cells (P = .036). We also found higher incidence of LMO2 expression in histologic grade G1/G2 cancers than in grade G3 cancers (P < .001). The median survival time of LMO2-positive patients was significantly longer than that of LMO2-negative patients (P < .001), and multivariate analyses revealed that high LMO2 expression was an independent predictor of longer survival (risk ratio, 0.432, P < .001). Even among patients with a positive operative margin, LMO2-positive patients had a significant survival benefit compared with LMO2-negative patients. We further performed a large cohort study (n = 113) to examine the LMO2 messenger RNA levels in formalin-fixed paraffin-embedded samples and found similar results. CONCLUSIONS: LMO2 is a promising marker for predicting a better prognosis in pancreatic cancer.

Original languageEnglish
Pages (from-to)712-719
Number of pages8
JournalNeoplasia
Volume11
Issue number7
DOIs
Publication statusPublished - Jan 1 2009

Fingerprint

Pancreatic Neoplasms
Neoplasms
Reverse Transcription
Survival
Polymerase Chain Reaction
Ductal Carcinoma
Messenger RNA
Oncogenes
Paraffin
Formaldehyde
Cultured Cells
Carcinogenesis
Cohort Studies
Multivariate Analysis
Epithelium
Immunohistochemistry
Odds Ratio
Incidence

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this

Nakata, K., Ouchida, K., Nagai, E., Hayashi, A., Miyasaka, Y., Kayashima, T., ... Tsuneyoshi, M. (2009). LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer. Neoplasia, 11(7), 712-719. https://doi.org/10.1593/neo.09418

LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer. / Nakata, Kohei; Ouchida, Kenoki; Nagai, Eishi; Hayashi, Akifumi; Miyasaka, Yoshihiro; Kayashima, Tadashi; Yu, Jun; Aishima, Shinichi; Oda, Yoshinao; Mizumoto, Kazuhiro; Tanaka, Masao; Tsuneyoshi, Masazumi.

In: Neoplasia, Vol. 11, No. 7, 01.01.2009, p. 712-719.

Research output: Contribution to journalArticle

Nakata, K, Ouchida, K, Nagai, E, Hayashi, A, Miyasaka, Y, Kayashima, T, Yu, J, Aishima, S, Oda, Y, Mizumoto, K, Tanaka, M & Tsuneyoshi, M 2009, 'LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer', Neoplasia, vol. 11, no. 7, pp. 712-719. https://doi.org/10.1593/neo.09418
Nakata, Kohei ; Ouchida, Kenoki ; Nagai, Eishi ; Hayashi, Akifumi ; Miyasaka, Yoshihiro ; Kayashima, Tadashi ; Yu, Jun ; Aishima, Shinichi ; Oda, Yoshinao ; Mizumoto, Kazuhiro ; Tanaka, Masao ; Tsuneyoshi, Masazumi. / LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer. In: Neoplasia. 2009 ; Vol. 11, No. 7. pp. 712-719.
@article{a47a48eafb9a4175b0accf4db3508359,
title = "LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer",
abstract = "PURPOSE: LIM domain only 2 (LMO2) has been identified as a novel oncogene associated with carcinogenesis and better prognosis in several malignant tumors. We investigate the involvement of LMO2 in pancreatic cancer. EXPERIMENTAL DESIGN: We evaluated LMO2 expression in cultured cells, bulk tissues, and microdissected cells from pancreatic cancers by quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. RESULTS: Of 164 pancreatic cancers, 98 (60{\%}) were positive for LMO2 expression. LMO2 was more frequently detected in high-grade pancreatic intraepithelial neoplasia (PanIN) lesions (PanIN-2 and -3) than in low-grade PanIN lesions (PanIN-1A and -1B; P < .001) and was not detected in normal pancreatic ductal epithelium. The LMO2 messenger RNA levels were significantly higher in invasive ductal carcinoma cells than in normal pancreatic cells as evaluated by quantitative reverse transcription-polymerase chain reaction analyses of microdissected cells (P = .036). We also found higher incidence of LMO2 expression in histologic grade G1/G2 cancers than in grade G3 cancers (P < .001). The median survival time of LMO2-positive patients was significantly longer than that of LMO2-negative patients (P < .001), and multivariate analyses revealed that high LMO2 expression was an independent predictor of longer survival (risk ratio, 0.432, P < .001). Even among patients with a positive operative margin, LMO2-positive patients had a significant survival benefit compared with LMO2-negative patients. We further performed a large cohort study (n = 113) to examine the LMO2 messenger RNA levels in formalin-fixed paraffin-embedded samples and found similar results. CONCLUSIONS: LMO2 is a promising marker for predicting a better prognosis in pancreatic cancer.",
author = "Kohei Nakata and Kenoki Ouchida and Eishi Nagai and Akifumi Hayashi and Yoshihiro Miyasaka and Tadashi Kayashima and Jun Yu and Shinichi Aishima and Yoshinao Oda and Kazuhiro Mizumoto and Masao Tanaka and Masazumi Tsuneyoshi",
year = "2009",
month = "1",
day = "1",
doi = "10.1593/neo.09418",
language = "English",
volume = "11",
pages = "712--719",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer

AU - Nakata, Kohei

AU - Ouchida, Kenoki

AU - Nagai, Eishi

AU - Hayashi, Akifumi

AU - Miyasaka, Yoshihiro

AU - Kayashima, Tadashi

AU - Yu, Jun

AU - Aishima, Shinichi

AU - Oda, Yoshinao

AU - Mizumoto, Kazuhiro

AU - Tanaka, Masao

AU - Tsuneyoshi, Masazumi

PY - 2009/1/1

Y1 - 2009/1/1

N2 - PURPOSE: LIM domain only 2 (LMO2) has been identified as a novel oncogene associated with carcinogenesis and better prognosis in several malignant tumors. We investigate the involvement of LMO2 in pancreatic cancer. EXPERIMENTAL DESIGN: We evaluated LMO2 expression in cultured cells, bulk tissues, and microdissected cells from pancreatic cancers by quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. RESULTS: Of 164 pancreatic cancers, 98 (60%) were positive for LMO2 expression. LMO2 was more frequently detected in high-grade pancreatic intraepithelial neoplasia (PanIN) lesions (PanIN-2 and -3) than in low-grade PanIN lesions (PanIN-1A and -1B; P < .001) and was not detected in normal pancreatic ductal epithelium. The LMO2 messenger RNA levels were significantly higher in invasive ductal carcinoma cells than in normal pancreatic cells as evaluated by quantitative reverse transcription-polymerase chain reaction analyses of microdissected cells (P = .036). We also found higher incidence of LMO2 expression in histologic grade G1/G2 cancers than in grade G3 cancers (P < .001). The median survival time of LMO2-positive patients was significantly longer than that of LMO2-negative patients (P < .001), and multivariate analyses revealed that high LMO2 expression was an independent predictor of longer survival (risk ratio, 0.432, P < .001). Even among patients with a positive operative margin, LMO2-positive patients had a significant survival benefit compared with LMO2-negative patients. We further performed a large cohort study (n = 113) to examine the LMO2 messenger RNA levels in formalin-fixed paraffin-embedded samples and found similar results. CONCLUSIONS: LMO2 is a promising marker for predicting a better prognosis in pancreatic cancer.

AB - PURPOSE: LIM domain only 2 (LMO2) has been identified as a novel oncogene associated with carcinogenesis and better prognosis in several malignant tumors. We investigate the involvement of LMO2 in pancreatic cancer. EXPERIMENTAL DESIGN: We evaluated LMO2 expression in cultured cells, bulk tissues, and microdissected cells from pancreatic cancers by quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. RESULTS: Of 164 pancreatic cancers, 98 (60%) were positive for LMO2 expression. LMO2 was more frequently detected in high-grade pancreatic intraepithelial neoplasia (PanIN) lesions (PanIN-2 and -3) than in low-grade PanIN lesions (PanIN-1A and -1B; P < .001) and was not detected in normal pancreatic ductal epithelium. The LMO2 messenger RNA levels were significantly higher in invasive ductal carcinoma cells than in normal pancreatic cells as evaluated by quantitative reverse transcription-polymerase chain reaction analyses of microdissected cells (P = .036). We also found higher incidence of LMO2 expression in histologic grade G1/G2 cancers than in grade G3 cancers (P < .001). The median survival time of LMO2-positive patients was significantly longer than that of LMO2-negative patients (P < .001), and multivariate analyses revealed that high LMO2 expression was an independent predictor of longer survival (risk ratio, 0.432, P < .001). Even among patients with a positive operative margin, LMO2-positive patients had a significant survival benefit compared with LMO2-negative patients. We further performed a large cohort study (n = 113) to examine the LMO2 messenger RNA levels in formalin-fixed paraffin-embedded samples and found similar results. CONCLUSIONS: LMO2 is a promising marker for predicting a better prognosis in pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=67650501096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650501096&partnerID=8YFLogxK

U2 - 10.1593/neo.09418

DO - 10.1593/neo.09418

M3 - Article

C2 - 19568416

AN - SCOPUS:67650501096

VL - 11

SP - 712

EP - 719

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 7

ER -